RAGE Signaling in Melanoma Tumors

Despite recent progresses in its treatment, malignant cutaneous melanoma remains a cancer with very poor prognosis. Emerging evidences suggest that the receptor for advance glycation end products (RAGE) plays a key role in melanoma progression through its activation in both cancer and stromal cells....

Descripción completa

Detalles Bibliográficos
Autores principales: Olaoba, Olamide T., Kadasah, Sultan, Vetter, Stefan W., Leclerc, Estelle
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7730603/
https://www.ncbi.nlm.nih.gov/pubmed/33256110
http://dx.doi.org/10.3390/ijms21238989
_version_ 1783621721713016832
author Olaoba, Olamide T.
Kadasah, Sultan
Vetter, Stefan W.
Leclerc, Estelle
author_facet Olaoba, Olamide T.
Kadasah, Sultan
Vetter, Stefan W.
Leclerc, Estelle
author_sort Olaoba, Olamide T.
collection PubMed
description Despite recent progresses in its treatment, malignant cutaneous melanoma remains a cancer with very poor prognosis. Emerging evidences suggest that the receptor for advance glycation end products (RAGE) plays a key role in melanoma progression through its activation in both cancer and stromal cells. In tumors, RAGE activation is fueled by numerous ligands, S100B and HMGB1 being the most notable, but the role of many other ligands is not well understood and should not be underappreciated. Here, we provide a review of the current role of RAGE in melanoma and conclude that targeting RAGE in melanoma could be an approach to improve the outcomes of melanoma patients.
format Online
Article
Text
id pubmed-7730603
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-77306032020-12-12 RAGE Signaling in Melanoma Tumors Olaoba, Olamide T. Kadasah, Sultan Vetter, Stefan W. Leclerc, Estelle Int J Mol Sci Review Despite recent progresses in its treatment, malignant cutaneous melanoma remains a cancer with very poor prognosis. Emerging evidences suggest that the receptor for advance glycation end products (RAGE) plays a key role in melanoma progression through its activation in both cancer and stromal cells. In tumors, RAGE activation is fueled by numerous ligands, S100B and HMGB1 being the most notable, but the role of many other ligands is not well understood and should not be underappreciated. Here, we provide a review of the current role of RAGE in melanoma and conclude that targeting RAGE in melanoma could be an approach to improve the outcomes of melanoma patients. MDPI 2020-11-26 /pmc/articles/PMC7730603/ /pubmed/33256110 http://dx.doi.org/10.3390/ijms21238989 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Olaoba, Olamide T.
Kadasah, Sultan
Vetter, Stefan W.
Leclerc, Estelle
RAGE Signaling in Melanoma Tumors
title RAGE Signaling in Melanoma Tumors
title_full RAGE Signaling in Melanoma Tumors
title_fullStr RAGE Signaling in Melanoma Tumors
title_full_unstemmed RAGE Signaling in Melanoma Tumors
title_short RAGE Signaling in Melanoma Tumors
title_sort rage signaling in melanoma tumors
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7730603/
https://www.ncbi.nlm.nih.gov/pubmed/33256110
http://dx.doi.org/10.3390/ijms21238989
work_keys_str_mv AT olaobaolamidet ragesignalinginmelanomatumors
AT kadasahsultan ragesignalinginmelanomatumors
AT vetterstefanw ragesignalinginmelanomatumors
AT leclercestelle ragesignalinginmelanomatumors

Ejemplares similares